Search Details

Word: fuson (lookup in dictionary) (lookup stats)
Dates: all
Sort By: most recent first (reverse)


Usage:

...medicinal form for this purpose. One trouble was that it smelled like decayed fish and tasted lit tle better. Merck settled for selling its product, trade-named Cuemid, as a rem edy for the intolerable itching that often goes with jaundice. Duke University's Dr. Robert L. Fuson wondered wheth er, with its flavor improved, cholestyramine might not be used to lower cholesterol. Mead Johnson Laboratories, famed for many-flavored Metrecal, had the same idea. They gave it an orangeade taste, trade-named it Questran...

Author: /time Magazine | Title: Cardiology: Binding the Cholesterol | 10/13/1967 | See Source »

...physician or surgeon would be delighted to find a preventive or treat ment for atherosclerosis. Dr. Fuson had an added personal reason for investigating cholestyramine, he told the American College of Surgeons last week. In his early 30s, he already had a cholesterol reading above 250 mg., on the edge of the danger zone, and he weighed 226 Ibs. There was a depressing history of heart disease in his family...

Author: /time Magazine | Title: Cardiology: Binding the Cholesterol | 10/13/1967 | See Source »

...Fuson fed 101 dogs a high-fat diet; 79 of them got no cholestyramine...

Author: /time Magazine | Title: Cardiology: Binding the Cholesterol | 10/13/1967 | See Source »

...test patients who had been suffering from angina pectoris or recurrent small strokes, or who were unable to walk more than a few yards because of leg pain from deficient blood flow, 32 say they now feel better and some can walk farther. Dr. Fuson himself has slimmed to 172 Ibs. and has sent his cholesterol crashing down to the 40-50 mg. range that is normal for a newborn baby. He has done this without denying himself steaks and creamy desserts. "So," he says, "you can have your cake...

Author: /time Magazine | Title: Cardiology: Binding the Cholesterol | 10/13/1967 | See Source »

Duke's chief surgeon and Dr. Fuson's boss, Dr. David C. Sabiston Jr., staunchly endorsed the animal studies with cholestyramine. But he insists cautiously that there is as yet no scientific evidence that patients with artery disease have benefited. Their subjective impressions, he emphasized, are still only suggestive. Not until many of the test patients have had arterial examinations, both before and after taking cholestyramine, will it be possible to find physical proof...

Author: /time Magazine | Title: Cardiology: Binding the Cholesterol | 10/13/1967 | See Source »

| 1 | 2 | Next